Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation

被引：12

作者：

Tashan, Emine ^{[1
,2
]}

Karakucuk, Alptug ^{[1
]}

Celebi, Nevin ^{[1
]}

机构：

[1] Gazi Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkey

[2] Zoleant Pharmaceut Int, Istanbul, Turkey

来源：

AAPS PHARMSCITECH | 2020年 / 21卷 / 03期

关键词：

nanocrystal(s); oral drug delivery; factorial design; dissolution; physical characterization; FORMULATION DEVELOPMENT; DISSOLUTION RATE; NANOSUSPENSIONS; OLANZAPINE; QUALITY; BIOAVAILABILITY; ANTIPSYCHOTICS; SCHIZOPHRENIA; RISPERIDONE; MANAGEMENT;

D O I：

10.1208/s12249-020-01653-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The objective of the current study was to develop ziprasidone hydrochloride monohydrate (ZHM) nanocrystal-based orally dispersible tablet (ODT) formulations. Design of experiment approach was used to develop ODTs. The tablets were compressed using direct compression method and characterized with quality control tests. In vitro dissolution studies and Caco-2 cell permeability tests were executed. The hardness and friability values of nanocrystal-based ODTs were found 31.2 N and 1.05%, respectively. The disintegration time was below 10 s. Dissolution profile in pH 7.4 phosphate buffer showed that nanocrystal-based ODTs and commercial product were dissolved in 120 min 58.98% and 16%, respectively. In pH 7.4 phosphate buffer with SLS, sample groups dissolved above 85% at the end of the study. Permeability value and cumulative ZHM amount on the cells were improved with nanocrystals. In conclusion, the novel formulation of ZHM nanocrystal-based ODTs was successfully developed for alternative dosage form.

引用

页数：12

共 60 条

[31] Kozlowski-Gibson M, 2016, INT J LAW PSYCHIAT
[32] Improved dissolution and oral absorption by co-grinding active drug probucol and ternary stabilizers mixtures with planetary beads-milling method
Li, Fang
Li, Linsen
Wang, Shaoning
Yang, Yan
Li, Jia
Liu, Dongchun
Zhang, Sijie
Wang, Siling
Xu, Hui
[J]. ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 14 (06) : 649 - 657
[33] Ziprasidone Hydrocloride: What Role in the Management of Schizophrenia?
Mattei, Chiara
Rapagnani, Maria Paola
Stahl, Stephen M.
[J]. JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2011, 3 : 1 - 16
[34] Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds
Merisko-Liversidge, Elaine M.
Liversidge, Gary G.
[J]. TOXICOLOGIC PATHOLOGY, 2008, 36 (01) : 43 - 48
[35] An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine
Mishra, Saurabh M.
Rohera, Bhagwan D.
[J]. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2017, 22 (07) : 889 - 903
[36] Mullins CD, 2006, SCHIZOPHR RES
[37] Application of quality by design for optimization of spray drying process used in drying of Risperidone nanosuspension
Nair, Anu
Khunt, Dignesh
Misra, Manju
[J]. POWDER TECHNOLOGY, 2019, 342 : 156 - 165
[38] Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder
Novick, Diego
Montgomery, William
Treuer, Tamas
Koyanagi, Ai
Aguado, Jaume
Kraemer, Susanne
Haro, Josep Maria
[J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 1019 - 1025
[39] Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation
Oktay, Ayse N.
Karakucuk, Alptug
Ilbasmis-Tamer, Sibel
Celebi, Nevin
[J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 122 : 254 - 263
[40] Patil J, 2012, J PHARM SCI, V2, P26

← 1 2 3 4 5 6 →